Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation.N Engl J Med. 2017; 377: 454-464
- SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.Blood. 2020; 136: 157-170
- The utility and limitations of B- and T-cell gene rearrangement studies in evaluating lymphoproliferative disorders.Pathology. 2020; 53: 157-165
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; 2017.
- Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing.Proc Natl Acad Sci. 2016; 113: 9846-9851
- Somatic mutation and clonal expansions in human tissues.Genome Med. 2019; 11: 35
- Clonal hematopoiesis as a model for premalignant changes during aging.Exp Hematol. 2020; 83: 48-56
- Clonal hematopoiesis in human aging and disease.Science. 2019; 366: eaan4673
- Age-related clonal hematopoiesis associated with adverse outcomes.N Engl J Med. 2014; 371: 2488-2498
- Cancer therapy shapes the fitness landscape of clonal hematopoiesis.Nat Genet. 2020; 52: 1219-1226
- HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults.Nat Med. 2021; 27: 1006-1011
- Prediction of acute myeloid leukaemia risk in healthy individuals.Nature. 2018; 559: 400-404
- Somatic mutations precede acute myeloid leukemia years before diagnosis.Nat Med. 2018; 24: 1015-1023
- Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.N Engl J Med. 2014; 371: 2477-2487
- Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.N Engl J Med. 2017; 377: 111-121
- Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis.J Exp Med. 2021; 218: e20211872
- CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease.Blood. 2021; 138: 1727-1732
- Age-related cancer mutations associated with clonal hematopoietic expansion.Nat Med. 2014; 20: 1472-1478
- Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.Blood. 2017; 130: 742-752
- Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults.Nat Commun. 2016; 7: 12484
- Large-scale identification of clonal hematopoiesis and mutations recurrent in blood cancers.Blood Cancer Discov. 2021; 2: 226-237
- Clinical implications of genetic mutations in myelodysplastic syndrome.J Clin Oncol. 2017; 35: 968-997
- CHIP, CCUS, and other acronyms: definition, implications, and impact on practice.Am Soc Clin Oncol Educ Book. 2019; 39: 400-410
- Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma.J Clin Oncol. 2017; 35: 1598-1605
- Genetics of myelodysplastic syndromes.Cancers. 2021; 13: 3380
- Consortium on behalf of the CMD working group of the ICG, Gerstung M, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes.Blood. 2013; 122: 3616-3627
- Molecular landscape of therapy-related myeloid neoplasms in patients previously treated for gynecologic and breast cancers.Hemasphere. 2021; 5: e632
- Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.Leukemia. 2013; 27: 2081-2083
- Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.Blood. 2016; 128: 1246-1259
- Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.Nat Med. 2020; 26: 1549-1556
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.Blood. 2015; 125: 1367-1376
- New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.J Clin Oncol. 2012; 30: 820-829
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood. 2017; 129: 424-447
- Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.N Engl J Med. 2006; 355: 1456-1465
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.Blood. 2011; 118: 1208-1215
- Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.N Engl J Med. 2013; 368: 1781-1790
- Clinical significance of DNA variants in chronic myeloid neoplasms a report of the association for molecular pathology.J Mol Diagn. 2018; 20: 717-737
- Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.Lancet Haematol. 2020; 7: e226-e237
- Effect of mutation order on myeloproliferative neoplasms.N Engl J Med. 2015; 372: 601-612
- Classification and personalized prognosis in myeloproliferative neoplasms.N Engl J Med. 2018; 379: 1416-1430
- Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis.Leukemia. 2016; 30: 136-143
- Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.Leukemia. 2015; 29: 1115-1122
- Pure pathologic response is associated with improved overall survival in patients with advanced systemic mastocytosis receiving avapritinib in the phase I explorer study.Blood. 2020; 136: 37-38
- Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Hematology. 2020; 2020: 450-459
- ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.Leukemia. 2014; 28: 2206-2212
- Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.Blood. 2016; 128: 1408-1417
- Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.Haematologica. 2014; 99: e244-6
- An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.Blood. 2015; 125: 1857-1865
- The genomic landscape of juvenile myelomonocytic leukemia.Nat Genet. 2015; 47: 1326-1333
- Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: “2019 Update on Diagnosis, Risk-stratification, and Management.Am J Hematol. 2019; 94: 475-488
- Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.Nat Genet. 2013; 45: 18-24
- Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.Blood. 2019; 134: 867-879
- Are you a lumper or a splitter? Embrace the genomic spectrum of neutrophilic myeloid neoplasms.Hematologist. 2019; 17https://doi.org/10.1182/hem.v17.1.10150
- Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.N Engl J Med. 2013; 368: 2059-2074https://doi.org/10.1056/nejmoa1301689
- Germline mutations in MDS/AML predisposition disorders.Curr Opin Hematol. 2020; 28: 86-93
- The biology of B-progenitor acute lymphoblastic leukemia.Cold Spring Harb Perspect Med. 2020; 10: a034835
- Pediatric acute lymphoblastic leukemia.Haematologica. 2020; 105: 0
- The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia.Blood Adv. 2020; 4: 930-942
- Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia.J Clin Med. 2021; 10: 3792
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.Blood. 2011; 118: 6521-6528
- Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.Blood Adv. 2017; 1: 1657-1671
- Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.Blood Cancer J. 2017; 7: e607
- Intrachromosomal amplification of Chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children’s oncology group studies: a report from the children’s oncology group.J Clin Oncol. 2013; 31: 3397-3402
- Intrachromosomal amplification of chromosome 21 (iAMP21) detected by ETV6/RUNX1 FISH screening in childhood acute lymphoblastic leukemia: a case report.Revista Brasileira De Hematologia E Hemoterapia. 2013; 35: 369-371
- PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.Nat Genet. 2019; 51: 296-307
- Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.Proc Natl Acad Sci. 2018; 115: 201814397
- An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.Leukemia. 2014; 28: 70-77
- TP53 mutations in hypodiploid acute lymphoblastic leukemia.Cold Spring Harb Perspect Med. 2017; 7: a026286
- TP53 germline variations influence the predisposition and prognosis of B-Cell acute lymphoblastic leukemia in children.J Clin Oncol. 2018; 36: 591-599
- The genetics and mechanisms of T cell acute lymphoblastic leukaemia.Nat Rev Cancer. 2016; 16: 494-507
- FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors.J Exp Med. 2007; 204: 1813-1824
- Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.J Exp Med. 1996; 183: 2283-2291
- Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.Science. 2004; 306: 269-271
- Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.Cancer Cell. 2002; 1: 75-87
- The genetics and molecular biology of T-ALL.Blood. 2017; 129: 1113-1123
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.Nature. 2012; 481: 157-163
- Diagnostic challenges in T-lymphoblastic lymphoma, early T-cell precursor acute lymphoblastic leukemia or mixed phenotype acute leukemia.Medicine. 2018; 97: e12743
- Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.Lancet Oncol. 2009; 10: 147-156
- Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias.Blood. 1994; 84: 4038-4044
- Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.Nature. 2007; 446: 758-764
- High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-β and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response.Blood. 2009; 114: 1053-1062
- Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia.Blood. 2013; 122: 74-82
- The physiopathology of T- cell acute lymphoblastic leukemia: focus on molecular aspects.Front Oncol. 2020; 10: 273
- Genomic medicine, a practical guide.2019: 253-315https://doi.org/10.1007/978-3-030-22922-1_16
- Chronic lymphocytic leukaemia: from genetics to treatment.Nat Rev Clin Oncol. 2019; 16: 684-701
- Pattern and distribution of immunoglobulin VH gene usage in a cohort of B-CLl patients from a northeastern region of Italy.Diagn Mol Pathol. 2006; 15: 206-215
- B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.Br J Haematol. 2011; 153: 3-14
- Mutations driving CLL and their evolution in progression and relapse.Nature. 2015; 526: 525-530
- Genomic aberrations and survival in chronic lymphocytic leukemia.N Engl J Med. 2000; 343: 1910-1916
- Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.Blood. 2008; 112: 3322-3329
- NOTCH1 mutations in CLL associated with trisomy 12.Blood. 2012; 119: 329-331
- IGHV mutational status testing in chronic lymphocytic leukemia.Am J Hematol. 2017; 92: 1393-1397
- The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.Hematology. 2017; 2017: 329-337
- MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene.Blood Cancer J. 2017; 7: 651
- Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.Blood. 2014; 123: 3790-3796
- Clinical impact of MYD88 mutations in chronic lymphocytic leukemia.Blood. 2016; 127: 1611-1613
- Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.Blood. 2017; 129: 1469-1479
- Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression.Leukemia. 2014; 28: 2395-2398
- Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations.Haematologica. 2018; 103: 865-873
- Distinction of lymphoid and myeloid clonal hematopoiesis.Nat Med. 2021; 27: 1921-1927
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.Nature. 2000; 403: 503-511
- Genetics and pathogenesis of diffuse large B-Cell lymphoma.N Engl J Med. 2018; 378: 1396-1407
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med. 2018; 24: 679-690
- Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.Blood. 2017; 129: 1095-1102
- TET2 and DNMT3A mutations in human T-Cell lymphoma.N Engl J Med. 2012; 366: 95-96
- A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.Blood. 2014; 123: 1293-1296
- High-risk clonal hematopoiesis as the origin of AITL and NPM1-mutated AML.N Engl J Med. 2018; 379: 981-984
- Advances in understanding of angioimmunoblastic T-cell lymphoma.Leukemia. 2020; 34: 2592-2606
- Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis.J Clin Invest. 2017; 127: 2998-3012
- RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice.Blood. 2018; 132: 935-947
- Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma.Haematologica. 2016; 101: 757-763
- ITK/SYK translocation in angioimmunoblastic T-cell lymphoma.Am J Surg Pathol. 2013; 37: 1456-1457
- High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays.Leukemia. 2008; 22: 1891-1898
- Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms.Blood Adv. 2020; 4: 2261-2271
- Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.Blood. 2021; 137: 3237-3250
- Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias.Blood. 2021; 138: 662-673
- The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.Nat Genet. 2015; 47: 1465-1470
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood. 2016; 127: 2391-2405
- TET2 mutation in adult T-cell leukemia/lymphoma.J Clin Exp Hematop. 2015; 55: 145-149
- Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.Nat Genet. 2014; 46: 166-170
- Germline TET2 loss of function causes childhood immunodeficiency and lymphoma.Blood. 2020; 136: 1055-1066
- Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.Am J Hematol. 2020; 95: 548-567
- Genomic complexity of multiple myeloma and its clinical implications.Nat Rev Clin Oncol. 2017; 14: 100-113
- The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.Blood. 2003; 102: 2562-2567
- Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?.Blood. 2015; 126: 2713-2719
- Hypodiploidy is a major prognostic factor in multiple myeloma.Blood. 2001; 98: 2229-2238
- Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.Haematologica. 2013; 98: 1586-1592
- APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.Nat Commun. 2015; 6: 6997
- Genomic landscape and chronological reconstruction of driver events in multiple myeloma.Nat Commun. 2019; 10: 3835
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Blood. 2016; 127: 2955-2962
- The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.Haematologica. 2010; 95: 1221-1225
- Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).J Clin Oncol. 2010; 28: 4630-4634
- Prognostic significance of copy-number alterations in multiple myeloma.J Clin Oncol. 2009; 27: 4585-4590
- Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.Blood. 1998; 92: 802-809
- Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.Leukemia. 2014; 28: 675-679
- Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma.J Clin Oncol. 2015; 33: 3911-3920
- Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.Leukemia. 2018; 32: 2604-2616
- Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.J Clin Oncol. 2020; 38: 2380-2389
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.Blood. 2016; 128: 1226-1233
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
